Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Preferential Involvement of Tim-3 in the Regulation of Hepatic CD8+ T Cells in Murine Acute Graft-versus-Host Disease

Tsunekazu Oikawa, Yosuke Kamimura, Hisaya Akiba, Hideo Yagita, Ko Okumura, Hiroki Takahashi, Mikio Zeniya, Hisao Tajiri and Miyuki Azuma
J Immunol October 1, 2006, 177 (7) 4281-4287; DOI: https://doi.org/10.4049/jimmunol.177.7.4281
Tsunekazu Oikawa
*Department of Molecular Immunology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan;
†Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University Medical School, Tokyo, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yosuke Kamimura
*Department of Molecular Immunology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisaya Akiba
‡Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideo Yagita
‡Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ko Okumura
‡Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Takahashi
†Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University Medical School, Tokyo, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikio Zeniya
†Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University Medical School, Tokyo, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisao Tajiri
†Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University Medical School, Tokyo, Japan; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miyuki Azuma
*Department of Molecular Immunology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Induction of Tim-3 in aGVHD mice. A, The cryostat sections of the liver tissues from intact (a) and aGVHD (b) mice at 14 days after transfer were stained with anti-Tim-3 (RMT3–23) mAb. Scale bars = 25 μm. Control staining using isotype-matched rat Ig yielded negative results (data not shown). B and C, HMC and splenocytes from age-matched intact mice and the aGVHD mice 14 days after transfer were obtained. In B, cells were stained with FITC-conjugated anti-Tim-3 mAb, PerCP-conjugated anti-CD3 mAb and either allophycocyanin-conjugated anti-CD4 or anti-CD8 mAb, or with appropriate fluorochrome-conjugated control Igs. In C, cells were stained with FITC-conjugated anti-H-2Kd mAb, biotinylated-anti-Tim-3 mAb, followed by PE-streptavidin, PerCP-conjugated anti-CD3 mAb, and allophycocyanin-conjugated anti-CD4 or anti-CD8 mAb, or with appropriate fluorochrome-conjugated control Igs. Samples were analyzed by flow cytometry. If needed, an electronic gate was set on either the CD3+ (T), CD4+CD3+ (CD4 T), or CD8+CD3+ (CD8 T) lymphocytes; the expressions of the indicated Ags are shown as dot plots (four-decade log scale). Representative FACS profiles of ten mice in each group are shown. The quadrant markers have been positioned to include >98% of control Ig-stained cells (data not shown) in the lower left. The underlined values of the right corner in B show Tim-3 positive percentages within either CD3+, CD4+CD3+, or CD8+CD3+ T cells. The values of each quadrant in C are positive percentages within whole lymphocytes, CD4+ CD3+ or CD8+CD3+ T cells.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Coexpression of Tim-3 and Tim-3L on T cells in aGVHD mice. Splenocytes and HMC from intact and aGVHD mice were obtained as described in Fig. 1. Cells were stained with FITC-conjugated anti-Tim-3 mAb, purified Tim-3/B6-Ig, followed by biotinylated anti-mouse IgG2a mAb and PE-streptavidin, PerCP-conjugated anti-CD3 mAb, and allophycocyanin-conjugated anti-CD4 or anti-CD8 mAb or with appropriate fluorochrome-conjugated control Igs. Samples were analyzed by flow cytometry. If needed, an electronic gate was set on either CD3+ (T), CD4+CD3+ (CD4 T) or CD8+CD3+ (CD8 T) lymphocytes; the expressions of the indicated Ags are shown as dot plots (four-decade log scale). Representative FACS profiles of ten mice in each group are shown. The quadrant markers have been positioned to include >98% of control Ig-stained cells (data not shown) in the lower left. The underlined values of the right corner show Tim-3L positive percentages within CD3+, CD4+CD3+, or CD8+CD3+ T cells. The values of each quadrant in the double staining with Tim-3 and Tim-3L are positive percentages within CD4+ CD3+ or CD8+CD3+ T cells.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Expression of Tim-3 and Tim-3L on DCs and macrophages. Splenocytes and HMC from intact and aGVHD mice were stained with FITC-conjugated anti-CD11c or anti-F4/80 mAb, and either biotinylated anti-Tim-3 mAb, followed by PE-streptavidin, or unlabeled Tim-3Ig, followed by biotinylated anti-mouse IgG2a mAb and PE-streptavidin, or with appropriate fluorochrome-conjugated control Igs. Samples were analyzed by flow cytometry. Representative FACS profiles in each group of ten mice are displayed. The profiles of control Ig staining are shown in the left of each panel. The markers have been positioned to include >98% of control Ig-stained cells. A, the expressions of CD11c and either Tim-3 or Tim-3L within lymphocyte gate were analyzed. The underlined values of the right corner show Tim-3 or Tim-3L positive percentages within CD11c+ DCs. B, In the GVHD-induced mice, the F4/80+ cells did not contain a major population of forward scatter (FSC)high/side scatter (SSC)high characteristic macrophages. Therefore, an electronic gate was set on FSChigh/SSChigh cells, and then Tim-3 or Tim-3L expression was analyzed. The data are displayed as dot plots with Tim-3 or Tim-3L expression and FSC. Splenocytes and HMC within the macrophage gate contained 79% and 80% F4/80+ cells in an intact mouse and 58% and 30% F4/80+ cells in a GVHD mouse, respectively. The values are positive percentages in the FSChigh/SSChigh cells.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Effects of anti-Tim-3 mAb treatments on manifestation of acute GVHD. The BDF1 recipient mice transferred 5 × 107 B6 splenocytes were treated with either RMT3-23 (•), RMT3-8 (▪), or control rat IgG (○). Body weight was measured on the indicated days. The change in mean body weight (A), total cell numbers of splenocytes and HMC at 14 days after transfer (B) are shown. The values are the mean ± SD from three experiments with each group of five mice. ∗, Statistically different from control IgG-treated group (p < 0.05) (A). ∗, Statistically different (p < 0.05) (B). C, H&E staining of the livers from aGVHD mice. Representative staining from each group of three mice are shown. Scale bars = 25 μm.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Enhanced IFN-γ expression in T cells by the anti-Tim-3 mAb treatment. Splenocytes and HMC from aGVHD mice treated with either RMT3-23, RMT3-8, or control IgG were cultured with PMA and ionomycin in the presence of brefeldin A for 4 h. A, Cells were cell surface stained with FITC-conjugated CD8 mAb and PerCP-conjugated anti-CD3 mAb, or with appropriated fluorochrome-conjugated control Igs. After fixation and permeabilization, the cells were stained intracellularly with PE-conjugated anti-IFN-γ mAb or control Ig. B, Cells were cell surface stained with FITC-conjugated Tim-3 mAb and PerCP-conjugated anti-CD3 mAb, and either allophycocyanin-conjugated anti-CD4 or anti-CD8 mAb, or with appropriated fluorochrome-conjugated control Igs, and then stained intracellularly with PE-conjugated anti-IFN-γ mAb or control Ig. Samples were analyzed by flow cytometry. An electronic gate was set on either the CD3+ (A), CD3+CD4+ (CD4 T), or CD3+CD8+ (CD8 T) (B) cells; the expressions of the indicated Ags are shown as dot plots. Representative FACS profiles are shown. The quadrant markers have been positioned to include >98% of control Ig-stained cells (data not shown) in the lower left. Values are the mean ± SD for each group of ten mice.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    The anti-Tim-3 mAb treatment augmented cytotoxicity. Donor CD8+ T cells were isolated from pooled splenocytes and HMC from five aGVHD mice treated with either RMT3-23 (•), RMT3-8 (▴), or control IgG (○) and used as effector cells. Effector cells were cocultured with [3H]thymidine-labeled either P815 (H-2d), EL4 (H-2b), or RDM4 (H-2k) target cells for 6 h at the indicated E/T ratios. Cytotoxicity was measured as described in Materials and Methods. A, The values are the mean cytotoxicity ± SE from three independent experiments. B, Cytotoxicities against P815, EL4, and RDM4 by effector CD8+ T cells from control IgG-treated (□) or RMT3-23-treated (▪) aGVHD mice are shown. The E/T ratio was 25. ∗, Statistically different from control IgG-treated aGVHD mice (p < 0.05).

Tables

  • Figures
    • View popup
    Table I.

    Effects of anti-Tim-3 mAb treatments on T cell subpopulations in aGVHD-induced micea

    Group of MiceTreatmentCD3 T (%)CD4 T (%)CD8 T (%)CD25 (%)CD69 (%)
    CD4 TCD8 TCD4 TCD8 T
    Splenocytes
     Intact(−)34.5 ± 1.821.4 ± 0.912.2 ± 1.09.0 ± 0.30.5 ± 0.17.6 ± 0.62.1 ± 0.2
     aGVHDCont. IgG60.1 ± 8.3b27.4 ± 4.333.7 ± 6.1b21.2 ± 3.6b14.4 ± 6.4b31.7 ± 8.6b42.1 ± 4.8b
    RMT3-2359.1 ± 9.5b25.0 ± 6.431.5 ± 9.5b18.6 ± 4.1b15.2 ± 2.7b34.7 ± 4.4b46.2 ± 9.2b
    RMT3-862.0 ± 4.6b29.3 ± 5.2b33.7 ± 6.0b20.6 ± 4.5b14.2 ± 3.4b36.3 ± 5.3b43.3 ± 9.2b
    HMC
     Intact(−)59.5 ± 6.534.1 ± 4.019.9 ± 4.411.1 ± 2.70.6 ± 0.420.8 ± 3.46.3 ± 1.7
     aGVHDCont. IgG74.5 ± 5.2b11.5 ± 4.2b60.3 ± 13.2b25.1 ± 7.6b9.5 ± 2.6b37.8 ± 5.3b55.0 ± 9.3b
    RMT3-2375.1 ± 8.3b11.7 ± 5.2b63.9 ± 14.7b28.3 ± 3.9b11.0 ± 2.8b35.9 ± 5.9b62.5 ± 6.3b
    RMT3-869.5 ± 9.6b11.4 ± 1.8b59.5 ± 10.0b22.6 ± 3.2b9.0 ± 1.1b34.5 ± 7.6b62.1 ± 9.4b
    • a Splenocytes and HMC from age-matched BDF1 intact mice and control (Cont.) IgG or anti-Tim-3 mAb (RMT3-23 or RMT3-8)-treated aGVHD-induced mice at 14 days after transfer were analyzed. The percentages of CD3+, CD3+CD4+, and CD3+CD8− within whole splenocytes or HMC were presented as CD3, CD4 and CD8 T cells, respectively. The percentages of CD25+ or CD69+ cells within CD4 and CD8 T cells are shown. Values are the mean ± SD from four intact mice, and each group of ten aGVHD mice.

    • b Statistically different from the intact mice (p < 0.05). Data shown are representative of two experiments.

    • View popup
    Table II.

    Effects of anti-Tim-3 mAb treatments on cytokine expression in aGVHD-induced micea

    Group of MiceTreatmentIFN-γ (%)IL-10 (%)
    CD4 TCD8 TCD4 TCD8 T
    Splenocytes
     Intact(−)1.0 ± 0.13.5 ± 0.40.1 ± 0.00.1 ± 0.0
     aGVHDCont. IgG10.2 ± 2.5*16.8 ± 6.2*0.5 ± 0.3*0.7 ± 0.2*
    RMT3-2333.5 ± 10.5*†30.0 ± 6.5*†1.1 ± 0.3*†1.1 ± 0.6*
    RMT3-828.5 ± 7.5*†30.6 ± 7.1*†1.1 ± 0.5*†1.2 ± 0.5*
    HMC
     Intact(−)1.8 ± 0.53.5 ± 1.00.1 ± 0.10.3 ± 0.1
     aGVHDCont. IgG17.0 ± 8.4*27.4 ± 11.3*0.9 ± 0.3*2.3 ± 1.7*
    RMT3-2340.7 ± 11.3*†39.9 ± 5.5*†4.6 ± 2.1*†2.3 ± 1.4*
    RMT3-832.7 ± 7.1*†44.4 ± 5.8*†3.7 ± 2.2*†3.2 ± 2.3*
    • a Splenocytes and HMC from age-matched BDF1 intact mice and control (Cont.) IgG or anti-Tim-3 mAb (RMT3-23 or RMT3-8)-treated aGVHD-induced mice at 14 days after transfer were analyzed. The percentages of IFN-γ or IL-10-positive cells within CD3+CD4+ (CD4 T) or CD3+CD8+ (CD8 T) cells are shown. Values are the mean ± SD from four intact mice and each group of ten aGVHD mice. Statistically different from the intact mice (*, p < 0.05) and from the control IgG-treated mice (†, p < 0.05). Data shown are representative of two experiments.

PreviousNext
Back to top

In this issue

The Journal of Immunology: 177 (7)
The Journal of Immunology
Vol. 177, Issue 7
1 Oct 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preferential Involvement of Tim-3 in the Regulation of Hepatic CD8+ T Cells in Murine Acute Graft-versus-Host Disease
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Preferential Involvement of Tim-3 in the Regulation of Hepatic CD8+ T Cells in Murine Acute Graft-versus-Host Disease
Tsunekazu Oikawa, Yosuke Kamimura, Hisaya Akiba, Hideo Yagita, Ko Okumura, Hiroki Takahashi, Mikio Zeniya, Hisao Tajiri, Miyuki Azuma
The Journal of Immunology October 1, 2006, 177 (7) 4281-4287; DOI: 10.4049/jimmunol.177.7.4281

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preferential Involvement of Tim-3 in the Regulation of Hepatic CD8+ T Cells in Murine Acute Graft-versus-Host Disease
Tsunekazu Oikawa, Yosuke Kamimura, Hisaya Akiba, Hideo Yagita, Ko Okumura, Hiroki Takahashi, Mikio Zeniya, Hisao Tajiri, Miyuki Azuma
The Journal of Immunology October 1, 2006, 177 (7) 4281-4287; DOI: 10.4049/jimmunol.177.7.4281
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction
  • Regulatory Roles of IL-2 and IL-4 in H4/Inducible Costimulator Expression on Activated CD4+ T Cells During Th Cell Development
  • Induction of CD4+ T Cell Apoptosis as a Consequence of Impaired Cytoskeletal Rearrangement in UVB-Irradiated Dendritic Cells
Show more CELLULAR IMMUNOLOGY AND IMMUNE REGULATION

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606